Company / Cash & Equivalents
Rani Therapeutics Holdings, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$18.6M
FY2025
5-year range
$3.8M / $117.5M
FY2021-FY2025
Trend
+394.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +395% YoY in FY2025, a notable deviation from the 3-year average annual change of +77%.
Based on SEC 10-K filings.
$19M in FY2025 with a 3-year CAGR of -11.7%.
Declined from $27M to $19M over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -11.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 394.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.6M | +394.9% |
| FY2024 | $3.8M | -86.1% |
| FY2022 | $27.0M | -77.0% |
| FY2021 | $117.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026